Canton Strategic Holdings, Inc. logo

Canton Strategic Holdings, Inc. (CNTN)

Market Closed
17 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
2. 30
-0.04
-1.7094%
$
80.66M Market Cap
- P/E Ratio
- Div Yield
450,700 Volume
- Eps
$ 2.34
Previous Close
Add Transaction
Day Range
2.25 2.41
Year Range
1.08 9.08
Want to track CNTN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CNTN closed today lower at $2.3, a decrease of -1.7094% from yesterday's close, completing a monthly decrease of -18.7279% or -$0.53. Over the past 12 months, CNTN stock lost -27.8997%.
CNTN is not paying dividends to its shareholders.
The last earnings report, released on Jun 03, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.21%, based on the last three reports.
Canton Strategic Holdings, Inc. has completed 2 stock splits, with the recent split occurring on May 28, 2024.
The company's stock is traded on one exchange.

CNTN Chart

People also search for

AirSculpt Technologies Inc.
$ 4.45
+6.9712%
Veraxa Biotech Holding AG
$ 2.18
+6.3415%
Cellectis S.A. - ADR
$ 2.63
-1.4981%
Sutro Biopharma, Inc.
$ 23.57
-0.6743%
Turn Therapeutics Inc.
$ 9.12
+0.9967%

Canton Strategic Holdings, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
BO
Brian Oliveira Clear Street Group Inc.
652,243 $1.98M $1.52M -$453,308.89 -22.94%
RT
Robert Tutela Essex LLC
13,987 $43,300.29 $32,659.64 -$10,640.65 -24.57%
HFT
Hui Fai Tam Caitong International Asset Management Co. Ltd.
5 $16 $11.72 -$4.28 -26.75%
ST
Steven Trigili Garden State Investment Advisory Services LLC
15,197 $46,047 $35,560.98 -$10,486.02 -22.77%
Neisy Arnez
Neisy Arnez Drucker Wealth 3.0, LLC
25,337 $74,844.99 $58,936.4 -$15,908.59 -21.26%

Canton Strategic Holdings, Inc. (CNTN) FAQ

What is the stock price today?

The current price is $2.30.

On which exchange is it traded?

Canton Strategic Holdings, Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is CNTN.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 80.66M.

Has Canton Strategic Holdings, Inc. ever had a stock split?

Canton Strategic Holdings, Inc. had 2 splits and the recent split was on May 28, 2024.

Canton Strategic Holdings, Inc. Profile

Biotechnology Industry
Healthcare Sector
Mark Wendland CEO
NASDAQ (NMS) Exchange
432705309 CUSIP
US Country
12 Employees
- Last Dividend
28 May 2024 Last Split
- IPO Date

Overview

Canton Strategic Holdings, Inc. is a forward-thinking company dedicated to integrating blockchain technology within institutional finance through the use of Canton Coin and the development of the Canton network. The company's goal is to spearhead the adoption of blockchain solutions, fostering the digitization of financial markets. In addition to blockchain initiatives, Canton Strategic Holdings is engaged in the research and development of innovative medical technologies. Noteworthy projects include GV104 and GV023, which focus on addressing critical healthcare challenges, particularly in military and emergency response contexts. Originally founded as Tharimmune, Inc. in 2017, the company rebranded to Canton Strategic Holdings, Inc. in February 2026, with its headquarters located in Red Bank, New Jersey.

Products and Services

  • Canton Coin: A digital currency designed to facilitate transactions within the Canton network, aimed at promoting the broader adoption of blockchain within institutional finance.
  • Canton Network: A framework supporting the utilization of blockchain technology to enhance the efficiency and transparency of financial markets.
  • GV104: A buccal film technology developed to address respiratory and/or nervous system depression, specifically for use in military personnel and chemical incident responders. This product has successfully completed Phase 1 trials.
  • GV023: An oral formulation of infliximab, designed to overcome limitations of traditional IV treatments by eliminating the need for repeated intravenous infusions, thus alleviating the treatment burden for patients.

Contact Information

Address: 34 Shrewsbury Avenue
Phone: 732 889 3111